Download PDF
Semin Respir Crit Care Med 2018; 39(05): 625-634
DOI: 10.1055/s-0038-1675334
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Emerging Role of Extracorporeal Support in Acute and Acute-on-Chronic Liver Failure: Recent Developments

Andrew J. MacDonald
1   Division of General Surgery, University of Alberta, Edmonton, Alberta, Canada
,
Constantine J. Karvellas
2   Division of Gastroenterology (Liver Unit), Department of Critical Care Medicine, University of Alberta, Edmonton, Alberta, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
28 November 2018 (online)

    Permissions and Reprints

Abstract

Acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) are life-threatening illnesses requiring intensive care admission and potentially liver transplantation. Artificial extracorporeal liver support (ECLS) systems remove water-soluble and albumin-bound toxins to maintain normal serum chemistry, prevent further hepatic/organ system damage, and create an environment for potential hepatic regeneration/recovery (ALF) or bridge to liver transplantation (ALF and ACLF). Use of artificial ECLS has been studied in both ALF and ACLF. Artificial ECLS systems have been found to be safe and have demonstrated the following benefits: improvement of biochemistries, hemodynamic status, and hepatic encephalopathy. Despite this, only one prospective randomized controlled trial examining the use of high-volume plasma exchange has demonstrated improvement in transplant-free survival. Bioartificial (cell-based) ECLS systems build on the technology of artificial systems, incorporating living hepatocytes in a bioactive platform to further mimic endogenous hepatic detoxification and synthetic functions. Currently, no bioartificial system has been found to confer a mortality benefit; however, these platforms offer the greatest potential for future development.

Keywords

extracorporeal liver support - albumin dialysis - acute liver failure - acute-on-chronic liver failure - extracorporeal liver-assist device - liver transplantation
 

  • References

  • 1 O'Grady JG, Williams R. Classification of acute liver failure. Lancet 1993; 342 (8873): 743
    CrossrefPubMedGoogle Scholar
  • 2 Lee WM, Squires Jr RH, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology 2008; 47 (04) 1401-1415
    PubMedGoogle Scholar
  • 3 Larson AM, Polson J, Fontana RJ. , et al; Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42 (06) 1364-1372
    CrossrefPubMedGoogle Scholar
  • 4 Fagan E, Wannan G. Reducing paracetamol overdoses. BMJ 1996; 313 (7070): 1417-1418
    CrossrefPubMedGoogle Scholar
  • 5 Ware AJ, D'Agostino AN, Combes B. Cerebral edema: a major complication of massive hepatic necrosis. Gastroenterology 1971; 61 (06) 877-884
    PubMedGoogle Scholar
  • 6 Bernal W, Wendon J. Acute liver failure; clinical features and management. Eur J Gastroenterol Hepatol 1999; 11 (09) 977-984
    CrossrefPubMedGoogle Scholar
  • 7 Albrecht J, Norenberg MD. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology 2006; 44 (04) 788-794
    CrossrefPubMedGoogle Scholar
  • 8 Sarin SK, Kumar A, Almeida JA. , et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009; 3 (01) 269-282
    CrossrefPubMedGoogle Scholar
  • 9 Sarin SK, Kedarisetty CK, Abbas Z. , et al; APASL ACLF Working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int 2014; 8 (04) 453-471
    CrossrefPubMedGoogle Scholar
  • 10 Bajaj JS, O'Leary JG, Reddy KR. , et al; North American Consortium for the Study of End-Stage Liver Disease (NACSELD). Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 2014; 60 (01) 250-256
    CrossrefPubMedGoogle Scholar
  • 11 Moreau R, Jalan R, Gines P. , et al; CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144 (07) 1426-1437 , 1437.e1–1437.e9
    CrossrefPubMedGoogle Scholar
  • 12 Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut 2017; 66 (03) 541-553
    CrossrefPubMedGoogle Scholar
  • 13 Sen S, Williams R, Jalan R. Emerging indications for albumin dialysis. Am J Gastroenterol 2005; 100 (02) 468-475
    CrossrefPubMedGoogle Scholar
  • 14 Bismuth M, Funakoshi N, Cadranel J-F, Blanc P. Hepatic encephalopathy: from pathophysiology to therapeutic management. Eur J Gastroenterol Hepatol 2011; 23 (01) 8-22
    CrossrefPubMedGoogle Scholar
  • 15 Nyberg SL. Bridging the gap: advances in artificial liver support. Liver Transpl 2012; 18 (Suppl. 02) S10-S14
    CrossrefPubMedGoogle Scholar
  • 16 Allen JW, Hassanein T, Bhatia SN. Advances in bioartificial liver devices. Hepatology 2001; 34 (03) 447-455
    CrossrefPubMedGoogle Scholar
  • 17 Arroyo V. Review article: albumin in the treatment of liver diseases--new features of a classical treatment. Aliment Pharmacol Ther 2002; 16 (Suppl. 05) 1-5
    PubMedGoogle Scholar
  • 18 Ortega R, Ginès P, Uriz J. , et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36 (4, Pt 1): 941-948
    CrossrefPubMedGoogle Scholar
  • 19 Sort P, Navasa M, Arroyo V. , et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341 (06) 403-409
    CrossrefPubMedGoogle Scholar
  • 20 Evans TW. Review article: albumin as a drug--biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002; 16 (Suppl. 05) 6-11
    CrossrefPubMedGoogle Scholar
  • 21 Mitzner S, Klammt S, Stange J, Schmidt R. Albumin regeneration in liver support-comparison of different methods. Ther Apher Dial 2006; 10 (02) 108-117
    CrossrefPubMedGoogle Scholar
  • 22 Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 1993; 17 (09) 809-813
    PubMedGoogle Scholar
  • 23 Hughes R, Ton HY, Langley P. , et al. Albumin-coated Amberlite XAD-7 resin for hemoperfusion in acute liver failure. Part II: in vivo evaluation. Artif Organs 1979; 3 (01) 23-26
    CrossrefPubMedGoogle Scholar
  • 24 Stange J, Mitzner SR, Risler T. , et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999; 23 (04) 319-330
    CrossrefPubMedGoogle Scholar
  • 25 Seige M, Kreymann B, Jeschke B, Schweigart U, Kopp KF, Classen M. Long-term treatment of patients with acute exacerbation of chronic liver failure by albumin dialysis. Transplant Proc 1999; 31 (1-2): 1371-1375
    CrossrefPubMedGoogle Scholar
  • 26 Mitzner SR, Stange J, Klammt S. , et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6 (03) 277-286
    CrossrefPubMedGoogle Scholar
  • 27 Heemann U, Treichel U, Loock J. , et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36 (4, Pt 1): 949-958
    CrossrefPubMedGoogle Scholar
  • 28 Hassanein TI, Tofteng F, Brown Jr RS. , et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46 (06) 1853-1862
    CrossrefPubMedGoogle Scholar
  • 29 Bañares R, Nevens F, Larsen FS. , et al; RELIEF Study Group. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013; 57 (03) 1153-1162
    CrossrefPubMedGoogle Scholar
  • 30 Novelli G, Rossi M, Pretagostini R. , et al. MARS (Molecular Adsorbent Recirculating System): experience in 34 cases of acute liver failure. Liver 2002; 22 (Suppl. 02) 43-47
    PubMedGoogle Scholar
  • 31 Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 2003; 9 (03) 290-297
    CrossrefPubMedGoogle Scholar
  • 32 El Banayosy A, Kizner L, Schueler V, Bergmeier S, Cobaugh D, Koerfer R. First use of the Molecular Adsorbent Recirculating System technique on patients with hypoxic liver failure after cardiogenic shock. ASAIO J 2004; 50 (04) 332-337
    CrossrefPubMedGoogle Scholar
  • 33 Saliba F, Camus C, Durand F. , et al. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann Intern Med 2013; 159 (08) 522-531
    CrossrefPubMedGoogle Scholar
  • 34 Karvellas CJ, Bagshaw SM, McDermid RC, Stollery DE, Gibney RT. Acetaminophen-induced acute liver failure treated with single-pass albumin dialysis: report of a case. Int J Artif Organs 2008; 31 (05) 450-455
    CrossrefPubMedGoogle Scholar
  • 35 Karvellas CJ, Bagshaw SM, McDermid RC, Stollery DE, Bain VG, Gibney RTN. A case-control study of single-pass albumin dialysis for acetaminophen-induced acute liver failure. Blood Purif 2009; 28 (03) 151-158
    CrossrefPubMedGoogle Scholar
  • 36 Sponholz C, Matthes K, Rupp D. , et al. Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure--a prospective, randomised crossover study. Crit Care 2016; 20: 2
    PubMedGoogle Scholar
  • 37 Schmuck RB, Nawrot G-H, Fikatas P, Reutzel-Selke A, Pratschke J, Sauer IM. Single pass albumin dialysis-a dose-finding study to define optimal albumin concentration and dialysate flow. Artif Organs 2017; 41 (02) 153-161
    CrossrefPubMedGoogle Scholar
  • 38 Falkenhagen D, Strobl W, Vogt G. , et al. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs 1999; 23 (01) 81-86
    CrossrefPubMedGoogle Scholar
  • 39 Laleman W, Wilmer A, Evenepoel P. , et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006; 10 (04) R108
    CrossrefPubMedGoogle Scholar
  • 40 Kribben A, Gerken G, Haag S. , et al; HELIOS Study Group. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012; 142 (04) 782-789.e3
    CrossrefPubMedGoogle Scholar
  • 41 Winters JL. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 7-12
    CrossrefPubMedGoogle Scholar
  • 42 Kondrup J, Almdal T, Vilstrup H, Tygstrup N. High volume plasma exchange in fulminant hepatic failure. Int J Artif Organs 1992; 15 (11) 669-676
    CrossrefPubMedGoogle Scholar
  • 43 Nakamura T, Ushiyama C, Suzuki S. , et al. Effect of plasma exchange on serum tissue inhibitor of metalloproteinase 1 and cytokine concentrations in patients with fulminant hepatitis. Blood Purif 2000; 18 (01) 50-54
    CrossrefPubMedGoogle Scholar
  • 44 Larsen FS, Hansen BA, Ejlersen E. , et al. Cerebral blood flow, oxygen metabolism and transcranial Doppler sonography during high-volume plasmapheresis in fulminant hepatic failure. Eur J Gastroenterol Hepatol 1996; 8 (03) 261-265
    CrossrefPubMedGoogle Scholar
  • 45 Larsen FS, Ejlersen E, Hansen BA, Mogensen T, Tygstrup N, Secher NH. Systemic vascular resistance during high-volume plasmapheresis in patients with fulminant hepatic failure: relationship with oxygen consumption. Eur J Gastroenterol Hepatol 1995; 7 (09) 887-892
    PubMedGoogle Scholar
  • 46 Larsen FS, Schmidt LE, Bernsmeier C. , et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol 2016; 64 (01) 69-78
    CrossrefPubMedGoogle Scholar
  • 47 McKenzie TJ, Lillegard JB, Nyberg SL. Artificial and bioartificial liver support. Semin Liver Dis 2008; 28 (02) 210-217
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Cao S, Esquivel CO, Keeffe EB. New approaches to supporting the failing liver. Annu Rev Med 1998; 49: 85-94
    CrossrefPubMedGoogle Scholar
  • 49 Park JK, Lee DH. Bioartificial liver systems: current status and future perspective. J Biosci Bioeng 2005; 99 (04) 311-319
    CrossrefPubMedGoogle Scholar
  • 50 Sussman NL, Chong MG, Koussayer T. , et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 1992; 16 (01) 60-65
    CrossrefPubMedGoogle Scholar
  • 51 Ellis AJ, Hughes RD, Wendon JA. , et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24 (06) 1446-1451
    CrossrefPubMedGoogle Scholar
  • 52 Thompson J, Jones N, Al-Khafaji A. , et al; VTI-208 Study Group. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial. Liver Transpl 2018; 24 (03) 380-393
    CrossrefPubMedGoogle Scholar
  • 53 Demetriou AA, Brown Jr RS, Busuttil RW. , et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004; 239 (05) 660-667 , discussion 667–670
    CrossrefPubMedGoogle Scholar
  • 54 Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003; 289 (02) 217-222
    CrossrefPubMedGoogle Scholar
  • 55 Stutchfield BM, Simpson K, Wigmore SJ. Systematic review and meta-analysis of survival following extracorporeal liver support. Br J Surg 2011; 98 (05) 623-631
    CrossrefPubMedGoogle Scholar
  • 56 Zheng Z, Li X, Li Z, Ma X. Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: a meta-analysis and meta-regression. Exp Ther Med 2013; 6 (04) 929-936
    CrossrefPubMedGoogle Scholar
  • 57 Antoniades CG, Berry PA, Wendon JA, Vergani D. The importance of immune dysfunction in determining outcome in acute liver failure. J Hepatol 2008; 49 (05) 845-861
    CrossrefPubMedGoogle Scholar
  • 58 Nyberg SL, Hardin J, Amiot B, Argikar UA, Remmel RP, Rinaldo P. Rapid, large-scale formation of porcine hepatocyte spheroids in a novel spheroid reservoir bioartificial liver. Liver Transpl 2005; 11 (08) 901-910
    CrossrefPubMedGoogle Scholar
  • 59 Glorioso JM, Mao SA, Rodysill B. , et al. Pivotal preclinical trial of the spheroid reservoir bioartificial liver. J Hepatol 2015; 63 (02) 388-398
    CrossrefPubMedGoogle Scholar
  • 60 Cardoso FS, Gottfried M, Tujios S, Olson JC, Karvellas CJ. ; US Acute Liver Failure Study Group. Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure. Hepatology 2017; 67: 711-720
    PubMedGoogle Scholar